ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost CHF4 billion ($4 billion) in market cap on Wednesday, despite reporting 3Q18 revenues slightly above the Street's expectations.
Roche gained RG6125, a humanized mAb against cadherin 11 (Cad-11; CDH11), through its 2015 acquisition of Adheron Therapeutics Inc. for $105 million up front (see “Roche to Acquire Adheron”)...
BCIQ Company Profiles